The PAX5 gene is altered in 30% of BCP-ALL patients and PAX5 chromosomal translocations account for 2-3% of cases. Although PAX5 fusion genes significantly affect the transcription of PAX5 target genes, their role in sustaining leukemia cell survival is poorly understood. In an in vitro model of PAX5/ETV6 leukemia, we demonstrated that Lck hyperactivation, and down-regulation of its negative regulator Csk, lead to STAT5 hyperactivation and consequently to the up-regulation of the downstream effectors, cMyc and Ccnd2. More important, cells from PAX5 translocated patients show LCK up-regulation and over-activation, as well as STAT5 hyper-phosphorylation, compared to PAX5 wt and PAX5 deleted cases. As in BCR/ABL1 positive ALL, the hyper-activation of STAT5 pathway can represent a survival signal in PAX5 translocated cells, alternative to the pre-BCR, which is down-regulated. The LCK inhibitor BIBF1120 selectively reverts this phenomenon both in the murine model and in leukemic primary cells. LCK inhibitor could therefore represent a suitable candidate drug to target this subgroup of ALL patients.

Cazzaniga, V., Bugarin, C., Bardini, M., Giordan, M., Te Kronnie, G., Basso, G., et al. (2015). LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients. ONCOTARGET, 6(3), 1569-1581 [10.18632/oncotarget.2807].

LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients

CAZZANIGA, VALERIA
Primo
;
BARDINI, MICHELA;BIONDI, ANDREA;FAZIO, GRAZIA
Penultimo
;
Cazzaniga, G.
2015

Abstract

The PAX5 gene is altered in 30% of BCP-ALL patients and PAX5 chromosomal translocations account for 2-3% of cases. Although PAX5 fusion genes significantly affect the transcription of PAX5 target genes, their role in sustaining leukemia cell survival is poorly understood. In an in vitro model of PAX5/ETV6 leukemia, we demonstrated that Lck hyperactivation, and down-regulation of its negative regulator Csk, lead to STAT5 hyperactivation and consequently to the up-regulation of the downstream effectors, cMyc and Ccnd2. More important, cells from PAX5 translocated patients show LCK up-regulation and over-activation, as well as STAT5 hyper-phosphorylation, compared to PAX5 wt and PAX5 deleted cases. As in BCR/ABL1 positive ALL, the hyper-activation of STAT5 pathway can represent a survival signal in PAX5 translocated cells, alternative to the pre-BCR, which is down-regulated. The LCK inhibitor BIBF1120 selectively reverts this phenomenon both in the murine model and in leukemic primary cells. LCK inhibitor could therefore represent a suitable candidate drug to target this subgroup of ALL patients.
Articolo in rivista - Articolo scientifico
Leucemia lifoblastica acuta, PAX5, STAT5, LCK
English
1569
1581
13
Cazzaniga, V., Bugarin, C., Bardini, M., Giordan, M., Te Kronnie, G., Basso, G., et al. (2015). LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients. ONCOTARGET, 6(3), 1569-1581 [10.18632/oncotarget.2807].
Cazzaniga, V; Bugarin, C; Bardini, M; Giordan, M; Te Kronnie, G; Basso, G; Biondi, A; Fazio, G; Cazzaniga, G
File in questo prodotto:
File Dimensione Formato  
Cazzaniga V_Oncotarget 2015.pdf

accesso aperto

Dimensione 2.22 MB
Formato Adobe PDF
2.22 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/66148
Citazioni
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
Social impact